Sanofi Crecimiento futuro

Future controles de criterios 3/6

Sanofi se prevé un crecimiento anual de los beneficios y los ingresos de 5.8% y 5.2% respectivamente. Se prevé que el BPA sea de grow en 6.2% al año. Se prevé que la rentabilidad de los fondos propios sea de 13.4% en 3 años.

Información clave

13.8%

Tasa de crecimiento de los beneficios

13.6%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	14.8%
Tasa de crecimiento de los ingresos	4.8%
Rentabilidad financiera futura	14.3%
Cobertura de analistas	Good
Última actualización	19 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

BATS-CHIXE:SANP - Estimaciones futuras de los analistas y datos financieros pasados (EUR Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	52,156	9,604	10,183	12,773	11
12/31/2025	49,735	8,675	9,164	11,822	13
12/31/2024	46,281	7,460	6,763	9,637	14
12/31/2023	46,033	5,400	7,234	10,258	N/A
9/30/2023	45,699	9,066	N/A	N/A	N/A
6/30/2023	46,045	8,617	8,107	10,264	N/A
3/31/2023	46,199	8,357	N/A	N/A	N/A
12/31/2022	45,389	8,371	8,325	10,526	N/A
9/30/2022	44,348	6,409	N/A	N/A	N/A
6/30/2022	42,039	6,643	7,594	9,620	N/A
3/31/2022	40,342	6,666	N/A	N/A	N/A
12/31/2021	39,175	6,223	8,479	10,522	N/A
9/30/2021	38,496	6,174	N/A	N/A	N/A
6/30/2021	37,546	5,777	5,827	8,219	N/A
3/31/2021	36,939	12,197	N/A	N/A	N/A
12/31/2020	37,369	12,294	5,335	7,418	N/A
9/30/2020	37,650	11,224	N/A	N/A	N/A
6/30/2020	37,692	11,138	6,834	8,491	N/A
3/31/2020	38,234	3,453	N/A	N/A	N/A
12/31/2019	37,631	2,855	5,928	7,715	N/A
9/30/2019	36,940	3,179	N/A	N/A	N/A
6/30/2019	36,763	3,591	4,958	6,953	N/A
3/31/2019	36,264	4,439	N/A	N/A	N/A
12/31/2018	35,677	4,319	3,570	5,547	N/A
9/30/2018	35,316	4,041	N/A	N/A	N/A
6/30/2018	34,985	3,243	4,815	6,596	N/A
3/31/2018	35,428	3,539	N/A	N/A	N/A
12/31/2017	36,221	3,773	5,423	7,379	N/A
9/30/2017	36,400	4,593	N/A	N/A	N/A
6/30/2017	36,315	4,744	N/A	8,133	N/A
3/31/2017	35,677	4,682	N/A	N/A	N/A
12/31/2016	34,696	4,395	N/A	7,838	N/A
9/30/2016	34,349	4,195	N/A	N/A	N/A
6/30/2016	34,115	4,154	N/A	8,122	N/A
3/31/2016	34,569	4,440	N/A	N/A	N/A
12/31/2015	34,861	4,411	N/A	8,920	N/A
9/30/2015	37,201	5,292	N/A	N/A	N/A
6/30/2015	32,910	4,628	N/A	8,561	N/A
3/31/2015	35,074	4,329	N/A	N/A	N/A
12/31/2014	31,999	4,273	N/A	7,690	N/A
9/30/2014	33,484	4,112	N/A	N/A	N/A
6/30/2014	33,134	4,140	N/A	7,463	N/A
3/31/2014	33,074	3,812	N/A	N/A	N/A
12/31/2013	31,291	3,639	N/A	6,954	N/A
9/30/2013	33,424	3,127	N/A	N/A	N/A
6/30/2013	34,146	3,364	N/A	5,869	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: SANP(6.7% al año) es superior a la tasa de ahorro (1.5%).

Beneficios vs. Mercado: SANPSe prevé que los beneficios de la empresa (16.1% al año) crezcan más deprisa que el mercado UK (10.1% al año).

Beneficios de alto crecimiento: SANPSe prevé que los beneficios de la empresa crezcan, pero no significativamente.

Ingresos vs. Mercado: SANPSe prevé que los ingresos de la empresa (4.9% al año) crezcan más deprisa que los del mercado UK (4% al año).

Ingresos de alto crecimiento: SANPSe prevé que los ingresos de la empresa (4.9% al año) crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: SANPSe prevé que la Rentabilidad de los fondos propios de la empresa sea baja dentro de 3 años (13.4%).

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Sanofi Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Sanofi Reiterates Earnings Guidance for the Year 2023

Sanofi Provides Earnings Guidance for the Year 2023

Recent updates

Sanofi Announces Quebec's INESSS Recommends BEYFORTUS® for Prevention of RSV for All Infants 8 Months of Age and Younger

Sanofi Announces Launch of Verorab® (Sanofi Inactivated Rabies Vaccine) in the UK for Pre-exposure and Post-exposure Prophylaxis of Rabies in All Age Groups

Sanofi Announces Phase 2b Results for Amlitelimab Support Potential for Best-In-Class Maintenance of Response in Atopic Dermatitis

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts Dupixent®? (Dupilumab) Sbla for Treatment of Copd with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. and Sanofi Announces the Ministry of Health, Labor and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab) for the Treatment of Chronic Spontaneous Urticaria

Sanofi Reports Impairment of Intangible Assets for the Fourth Quarter Ended December 31, 2023

Full year 2023 earnings released: EPS: €4.31 (vs €6.69 in FY 2022)

Sanofi Announces CFO Changes, Effective April 1, 2024

Regeneron Pharmaceuticals, Inc. and Sanofi Announce That U.S. Food and Drug Administration Approves Dupixent®? (Dupilumab) for the Treatment of Children Aged 1 Year and Older with Eosinophilic Esophagitis

Sanofi to Report Q3, 2024 Results on Oct 25, 2024

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Updates the Label for Dupixent (Dpilumab)

Sanofi Appoints Brian Foard as Head of Specialty Care Global Business Unit and Member of Executive Committee

Sanofi to Report Q4, 2023 Results on Feb 01, 2024

Sanofi Announces Dupixent Significantly Reduced (34%) Exacerbations, Confirming Positive Published Results from the Landmark Phase 3 Boreas Trial

Sanofi to Report Q2, 2024 Results on Jul 25, 2024

Third quarter 2023 earnings released: EPS: €2.02 (vs €1.66 in 3Q 2022)

Sanofi Reiterates Earnings Guidance for the Year 2023

Investor sentiment deteriorates as stock falls 17%

Sanofi Announces Positive Results from a Phase 3 Trial Demonstrated the Efficacy and Safety Profile of Dupixent (Dupilumab) for Up to One Year (52 Weeks) in Children Aged 1 to 11 Years

Regeneron Pharmaceuticals, Inc. and Sanofi Provide Update on Dupixent®? (Dupilumab) sBLA for Chronic Spontaneous Urticaria

Sanofi Delivers First Medicines from Global Health Unit's Impact Brand Portfolio

Sanofi Reportedly Explores Potential Acquisition of Mirati Therapeutics

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepted for Priority Review

Sanofi S.A. and Sobi Announce Once-Weekly ALTUVIIIO Approved in Japan as A New Class of Factor VIII Therapy for Hemophilia A

Atnahs Pharma UK Limited acquired Global Central Nervous System Portfolio from Sanofi (ENXTPA:SAN).

Sanofi Announces Changes to Its Executive Committee

Sanofi, Annual General Meeting, Apr 30, 2024

Sanofi Announce that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices

Second quarter 2023 earnings released: EPS: €1.15 (vs €0.94 in 2Q 2022)

Sanofi Provides Earnings Guidance for the Year 2023

SK Bioscience and Sanofi Announce Positive Results from Phase II Study of 21-Valent Pneumococcal Conjugate Vaccine Candidate

Sanofi Approves Distribution of A Cash Dividend, Payable on June 1, 2023

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento